• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO

tetano

Editor, Senior Moderator
Cell Rep


. 2021 Feb 3;108761.
doi: 10.1016/j.celrep.2021.108761. Online ahead of print.
SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO


Jing Wu[SUP] 1 [/SUP], Yuheng Shi[SUP] 2 [/SUP], Xiaoyan Pan[SUP] 3 [/SUP], Shuang Wu[SUP] 1 [/SUP], Ruixia Hou[SUP] 1 [/SUP], Yong Zhang[SUP] 1 [/SUP], Tiansheng Zhong[SUP] 1 [/SUP], Hao Tang[SUP] 1 [/SUP], Wei Du[SUP] 1 [/SUP], Luying Wang[SUP] 1 [/SUP], Jing Wo[SUP] 1 [/SUP], Jingfang Mu[SUP] 3 [/SUP], Yang Qiu[SUP] 3 [/SUP], Ke Yang[SUP] 4 [/SUP], Lei-Ke Zhang[SUP] 5 [/SUP], Bang-Ce Ye[SUP] 6 [/SUP], Nan Qi[SUP] 7 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) is a current global health threat caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerging evidence indicates that SARS-CoV-2 elicits a dysregulated immune response and a delayed interferon (IFN) expression in patients, which contribute largely to the viral pathogenesis and development of COVID-19. However, underlying mechanisms remain to be elucidated. Here, we report the activation and repression of the innate immune response by SARS-CoV-2. We show that SARS-CoV-2 RNA activates the RIG-I-MAVS-dependent IFN signaling pathway. We further uncover that ORF9b immediately accumulates and antagonizes the antiviral type I IFN response during SARS-CoV-2 infection on primary human pulmonary alveolar epithelial cells. ORF9b targets the nuclear factor κB (NF-κB) essential modulator NEMO and interrupts its K63-linked polyubiquitination upon viral stimulation, thereby inhibiting the canonical IκB kinase alpha (IKKα)/β/γ-NF-κB signaling and subsequent IFN production. Our findings thus unveil the innate immunosuppression by ORF9b and provide insights into the host-virus interplay during the early stage of SARS-CoV-2 infection.

Keywords: COVID-19; RIG-I-MAVS signaling; SARS-CoV-2; innate immune response; interferon.
 
Back
Top Bottom